Literature DB >> 3003147

The idiotype-antiidiotype network in human autoimmunity.

N I Abdou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3003147     DOI： 10.1007/bf00915332

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  52 in total

1.  Autoimmunity and idiotypes.

Authors:  A Cooke; P M Lydyard; I M Roitt
Journal:  Lancet       Date:  1984-09-29       Impact factor: 79.321

Review 2.  Pathological expression of idiotypic interactions: immune complexes and cryoglobulins.

Authors:  M Goldman; J C Renversez; P H Lambert
Journal:  Springer Semin Immunopathol       Date:  1983

Review 3.  Induction of immune responses with anti-idiotypic antibodies: implications for the induction of protective immunity.

Authors:  D L Sacks; G H Kelsoe; D H Sachs
Journal:  Springer Semin Immunopathol       Date:  1983

4.  Normal mice express idiotypes related to autoantibody idiotypes of lupus mice.

Authors:  S K Datta; B D Stollar; R S Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

5.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

6.  Anti-idiotypic antibodies and autoantibodies.

Authors:  M Zanetti
Journal:  Ann N Y Acad Sci       Date:  1983       Impact factor: 5.691

7.  Anti-Fab' antibodies in rheumatoid arthritis. Measurement of the relative quantities incorporated in soluble immune complexes in sera and supernatants from cultured peripheral blood lymphocytes.

Authors:  H H Birdsall; M D Lidsky; R D Rossen
Journal:  Arthritis Rheum       Date:  1983-12

8.  Suppression of in vitro monoclonal human rheumatoid factor synthesis by antiidiotypic antibody. Target cells and molecular requirements.

Authors:  W J Koopman; R E Schrohenloher; J C Barton; E C Greenleaf
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

9.  Synthetic peptides corresponding to third hypervariable region of human monoclonal IgM rheumatoid factor heavy chains define an immunodominant idiotype.

Authors:  R D Goldfien; P P Chen; S Fong; D A Carson
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

10.  Idiotypic cross-reactions of monoclonal human lupus autoantibodies.

Authors:  Y Shoenfeld; D A Isenberg; J Rauch; M P Madaio; B D Stollar; R S Schwartz
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307
View more
  7 in total

1.  Presence of shared idiotypes in serum and immune complexes in patients with IgA nephropathy.

Authors:  J González-Cabrero; J Egido; J Sancho; F Moldenhauer
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

2.  Antiidiotypic antibodies against anti-DNA antibodies in sera of families of lupus patients.

Authors:  N I Abdou; R Suenaga; M Hatfield; M Evans; K M Hassanein
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

3.  Anti-idiotypic antibody against anti-DNA in sera of laboratory personnel exposed to lupus sera or nucleic acids.

Authors:  M Hatfield; M Evans; R Suenaga; K M Hassanein; N I Abdou
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

4.  Human IgG anti-F(ab')2 antibodies possess rheumatoid factor activity.

Authors:  S Hunt Gerardo; J E Persselin; R H Stevens
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

5.  Characterization of circulating idiotypes containing immune complexes and their presence in the glomerular mesangium in patients with IgA nephropathy.

Authors:  J González-Cabrero; J Egido; F Mampaso; M C Rivas; L Hernando
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

6.  Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin.

Authors:  M J Evans; R Suenaga; N I Abdou
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317

7.  In vitro T-cell functions specific to an anti-DNA idiotype and serological markers in patients with systemic lupus erythematosus (SLE).

Authors:  S Mendlovic; Y Shoenfeld; R Bakimer; R Segal; M Dayan; E Mozes
Journal:  J Clin Immunol       Date:  1988-05       Impact factor: 8.317
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.